Charcot-Marie-Tooth disease (CMT) is an umbrella term for inherited neuropathies affecting an estimated one in 2,500 people. Over 120 CMT and related genes have been identified and clinical gene panels often contain more than 100 genes. Such a large genomic space will invariantly yield variants of uncertain clinical significance (VUS) in nearly any person tested. This rise in number of VUS creates major challenges for genetic counseling. Additionally, fewer individual variants in known genes are being published as the academic merit is decreasing, and most testing now happens in clinical laboratories, which typically do not correlate their variants with clinical phenotypes. For CMT, we aim to encourage and facilitate the global capture of variant data to gain a large collection of alleles in CMT genes, ideally in conjunction with phenotypic information. The Inherited Neuropathy Variant Browser provides user-friendly open access to currently reported variation in CMT genes. Geneticists, physicians, and genetic counselors can enter variants detected by clinical tests or in research studies in addition to genetic variation gathered from published literature, which are then submitted to ClinVar biannually. Active participation of the broader CMT community will provide an advance over existing resources for interpretation of CMT genetic variation.
and intermediate forms (Dyck & Lambert, 1968; Reilly et al., 2011; Saporta & Shy, 2010) . Each major subtype is also classified based on mode of inheritance and genetic etiology. The advances in gene discovery enabled by next-generation sequencing (NGS) have revealed the extent of locus and allelic heterogeneity, with over 120 CMT and related genes identified (Timmerman, Strickland, & Zuchner, 2014) .
The "traditional" yield for definitive genetic CMT diagnosis is around 65%; however, diagnostic yields ranging from 19% to 53% have been observed from NGS approaches . Because ∼30% of CMT families remain without a genetic diagnosis (Fridman et al., 2015; Murphy et al., 2012; Saporta et al., 2011) , and recently discovered genes typically affect a small proportion of patients, there are likely additional unidentified causes.
With so many CMT genes, variants of unknown significance (VUS) are frequently identified during genetic testing. Standards and guidelines have been developed to interpret pathogenicity of VUS including their frequency within a large control population, cosegregation with disease status, and informatics/experimental evidence (MacArthur et al., 2014; Richards et al., 2015) . The task of categorizing individual alleles within these genes according to pathogenicity is daunting, yet highly clinically relevant. Data sharing and disease-variant databases are salient solutions to VUS interpretation. Efforts have been implemented to collect and store genetic variation from published literature and clinical laboratories, such as the Human Gene Mutation Database (HGMD), the Human Variome Project (HVP), and ClinVar (Bean & Hegde, 2016) . Such initiatives are necessary for and will lead to improved variant interpretation; however, currently, erroneous pathogenicity annotations in clinical diagnostic laboratories and in the published literature have introduced false pathogenicity claims into disease-variant databases (MacArthur et al., 2014; Manrai et al., 2016; Xue et al., 2012) . Discovering these errors and properly annotating novel variation will require cooperative curation efforts from experts within each disease community. open-access database of clinically observed variation (Rehm et al., 2015) .
Despite current variant collection efforts, the INC recognizes that a potentially large proportion of CMT genetic variation remains uncaptured. Within the academic setting, additional observations of published variation are now rarely shared after the initial gene discovery report (Bean, Tinker, da Silva, & Hegde, 2013) . Likewise, data sharing from clinical laboratories is limited owing to lack of funding and infrastructure, limited phenotype information, or company policies (Bean et al., 2013) . Another goal of the INVB is to encourage submission of all observed genetic variation as well as obtaining reports from clinical laboratories, when possible. To minimize burden on users, the INVB accepts direct submission of genetic variation, which will be synced biannually with ClinVar. The INVB's interactive rating system and discussion platform will lead to improved interpretation of VUS across the Mendelian CMT genes.
METHODS

Data collection, standardization, and curation
The CMT genetic variation data were collected from multiple sources including the HGMD, the Inherited Peripheral Neuropathies Mutation Database, results published by the Inherited Neuropathies Consortium, the supplemental data published by Athena and Quest Diagnostics, and manual data entry from collaborators (Cooper, Ball, & Krawczak, 1998) . All collected and submitted data conform to institutional review boards and ethical guidelines. The initial set of genes was selected based on the published literature; however, users have the ability to add new genes as they are described as causes of CMT and related disorders. For phenotypic data, the CMT neuropathy score was imported from the Inherited Neuropathies Consortium's natural history study when available (Fridman et al., 2015) . Additionally, each variant was annotated with the minor allele frequency from the Exome Aggregation Consortium (Karczewski et al. 2016 (Schwarz, Rödelsperger, Schuelke, & Seelow, 2010; Wildeman, van Ophuizen, Dunnen den, & Taschner, 2008) . The Variant Effect Predictor was used to fill in missing variant effect data (McLaren et al., 2016) . All publications require a valid PubMed ID, and the title, author, and reference metadata is automatically retrieved and saved in the database.
Continuing the community-driven nature of this database, CMT researchers and clinicians have begun to adopt individual genes to curate. In the initial release, each adoptee verified the genetic variation data. For future curation, biannual reports of new submissions will be generated for manual review and curation.
Database creation and user interface
The INVB is built using PHP scripts for the backend and a relational database (Microsoft SQL Server) to store the data. The curated data were imported into the corresponding tables within the database using SQL scripts. The database has audit capability to track userinitiated changes. The graphical user interface for the Web page was built using the AngularJS framework, Bootstrap stylesheet, and HTML.
Data submission
The INVB is designed for simple and fast variation upload. User registration and log-in is required for any variant submissions. Each variant submission is assigned a randomly generated family ID to allow for genotypic data. This family ID is displayed in the public browser. The submitter has the option to input a private family ID during submission. The private ID, along with the matched public ID, will be available only to the submitter in his/her account page. The purpose of the optional private family ID is to assist submitters with data entry tracking to minimize duplicate entries. Query results are displayed in graph and table format. For each gene, the graphic result contains three viewing options: Allele, CMTNS (CMT neuropathy score) , or Exome Aggregation Consortium minor allele frequency (ExAC MAF) (Karczewski et al. 2016 ) ( Figure 1C ). Each plot uses the "Mutations Needle Plot" and displays the known protein sites and domains, retrieved from NCBI. The default '"allele" plot displays the protein location of each allele, count of observations, and variant type. The "CMTNS" and "ExAC" plots require available data for at least one variant within the gene in order to be displayed. The "CMTNS" plot shows CMTNS for each allele and the associated age at onset. The "ExAC" plot displays the ExAC MAF (release 0.3.1). Currently, not all genes have the full set of annotated information available.
RESULTS
Graphical user interface
The table result consists of seven sortable columns: gene, variant, protein notation, variant type, rating, links, and data source (Figure 2) . The data are grouped by primary variant into a gray expandable row (Figure 2A ). The expanded view shows detailed information about each variant ( Figure 2B ). In the expanded view, each variant is grouped by the public family ID ( Figure 2C ) and the observed genotype and zygosity ( Figure 2D ). For example, the variant in Figure 2E is shown twice to indicate its homozygous zygosity (HOM). Alternatively, Figure 2F displays the variant in the compound heterozygous state (HET). For easy submission, additional families with the same genotype can be added by clicking the button next to the zygosity status ( Figure 2G ). Each family's data source can be viewed, edited, or deleted in the expanded view ( Figure 2H ). Lastly, each individual variant can be rated through the variant rating system, described below ( Figure 2I ).
Variant rating system
The variant pathogenicity rating system is based upon the standardized terminology of the American College of Medical Genetics and Genomics (ACMG) (Richards et al., 2015) . The average rating of a variant is represented as a five-star system in the table of query result.
Each star corresponds to the ACMG terminology: benign, likely benign, uncertain significance, likely pathogenic, pathogenic (starting from 1 star rating). Registered users can rate a variant within the result table and can provide additional comments about their rating ( Figure 2I) . A history of all ratings and comments will be maintained for each variant. Importantly, any individual rating allows for free-text commenting. This creates a track record of evidence in support of the specific rating.
Database summary statistics
The INVB currently contains 3,809 unique variants within 82 genes.
The genes currently contain a median of 16 variants, an interquartile range from 4.0 to 69.5, and a maximum of 720 variants in GJB1 (Figure 3A) . A total of 4,558 unrelated families exist with the following genotypes: 2,244 heterozygous, 528 homozygous, and 301 compound heterozygous ( Figure 3B ). Currently, 1,475 families were reported from clinical laboratories without genotypic information. All new submissions will require genotypic data. The currently available phenotypic data highlights the clinical variability of CMT with an age of onset range of 9-75 years and a CMT neuropathy score of 2-24 (Figure 3C) . The majority of variants are coding (Figure 3D) . However, we encourage the submission of noncoding variation to cover the full spectrum of the genetic architecture of CMT. As whole-genome sequencing usage increases we expect the amount of noncoding variation to expand. The variant rating system is becoming a popular feature with 179 ratings to date ( Figure 3E ).
F I G U R E 1 Overview of Inherited Variant Browser homepage and search options. A:
The quick search field displays an autocomplete dropdown option and can be queried by: gene name, variant coding position, variant protein position, publication title, publication author, variant type, and data source. B: The multiselect searches enable multiple selections across gene, variant type, and data source. These fields allow users to conduct complex queries, such as all missense and LoF variants reported in published articles in MFN2, GJB1, and GDAP1. C: For single gene queries, variants can be displayed in three plots: allele, CMTNS, and ExAC. These plots can be toggled or hidden by selecting the buttons above each plot
Usage examples
In order to illustrate use cases for the variant browser, we provide two examples that highlight current and future advantages.
1. Locus and allelic frequency are determinants of expected maximum tolerated population allele frequencies and directly affect pathogenicity evaluation (Whiffin et al., 2017; Wiel et al. 2017 ).
In addition, genic sub-regions, such as protein domains and exons, have been shown valuable in determining genetic tolerance and thus pathogenicity (Gussow, Petrovski, Wang, Allen, & Goldstein, 2016) . For example, nonsynonymous variants are observed across nearly all of GJB1, while such variants are clustered at specific protein domains in DNM2 ( Figure 4A ). By cataloging the genetic variation (and phenotypic details) observed in CMT genes, CMT-specific genetic tolerance metrics can be developed. Genetic tolerance metrics support clinical VUS interpretation as well as reveal insights into the biological mechanisms of disease genes (Samocha et al. 2017 ).
The Variant Rating System is a low threshold tool that allows clin-
icians and researchers to share and record supporting evidence for variant interpretation. Figure 4B shows a real example of a commentary from a user regarding conflicting data: the frequency of a variant in a healthy population (indicates benign) and abnormal electrophysiological data (indicates pathogenic). For quick interpretation from the table view, the variant is rated as two-star "likely benign," whereas the detailed view shows users' comments.
The intuitive user interface allows for simple and fast user interactions, which will greatly improve the community's ability to interpret VUS.
DISCUSSION
At a time when clinical multigene testing in highly heterogeneous
Mendelian diseases is becoming a standard, the burden of VUS has risen to a point where it obstructs high quality diagnosis in individual patients. Neurologists and genetic counselors working with CMT patients are confronted by this issue daily. Although there are multiple potential solutions conceivable to address this problem, including future functional genomics platforms, a sensible and cost effective way forward is the comprehensive and public mapping of disease associated variation to disease-causing genes. We have collected CMT-specific genetic variation, along with genotypic and phenotypic data when available, from published literature, clinical lab reports, and our own in-house data. We then created the interactive, Web-based mented an interactive rating system of genetic variation based on standardized terminology from the ACMG (Richards et al., 2015) . The rating history for each variant, along with comments from raters, will be maintained to provide a rich perspective to users. The INC is encouraging its global membership to submit observed pathogenic variation, VUS and polymorphisms to the INVB. This platform enables a joint effort by the global CMT expert community to store, share, and discuss genetic variation to resolve VUS.
Although the frequency of a DNA variant within an unaffected population helps to categorize benign variation, only repeated observation of a variant in affected families will strengthen pathogenic classification. The continued aggregation of both disease-associated and benign variation will remain essential to further resolve VUS (Bean et al., 2013) . Currently, 25%-30% of variants in databases can be clearly classified as benign or pathogenic (Bean & Hegde, 2016) . We see an opportunity to create enthusiasm and attention in the CMT field to participate in the important task of collecting individual genetic test results from many clinics and different parts of the world. We were able to assemble an international group of experts committed to working together to classify variation and we hope the CMT community Similarly, large-scale population data, such as ExAC, a collection of over ∼60,000 exomes from patients unaffected by severe pediatric diseases, has revealed previously reported pathogenic alleles as too common relative to the prevalence of CMT (Minikel et al., 2016) . We therefore incorporated ExAC data into the INVB (Karczewski et al. 2016) .
Benign variants falsely assigned as pathogenic have been revealed and reported disease variant penetrance has been re-evaluated, such as p.Arg468His in MFN2. This variant has been implicated in variant screening studies at least four times; yet, the relatively high count of 265 heterozygous alleles out of 115,542 ExAC chromosomes excludes the variant as a causative, high penetrance allele in a dominant rare disease (Braathen, Sand, Lobato, Høyer, & Russell, 2010; Casasnovas et al. 2010; Engelfried et al., 2006; McCorquodale et al., 2011) .
Though variant databases excel in providing overall allele frequencies, most capture genetic variants without listing individual patients and their genotypes; however, this information may contribute to variant interpretation (Lanthaler et al., 2014) . Without knowing the heterozygous, homozygous, or compound heterozygous state, it may be difficult to determine causality in a recessive disorder. Furthermore, In order to benefit the wider scientific community, all collected data have been submitted to ClinVar-a public archive of the interpreted clinical significance of variants for reported conditions at the National Center for Biotechnology Information (Landrum et al., 2016) . ClinVar was developed to provide access to the interpretation of human variation and is an effort critical to genomic medicine (Landrum et al., 2014) .
As avid supporters of the ClinVar initiative, we recommend the entire community to submit variation data directly to the database. However, we have implemented direct submission to the INVB to collect data inappropriate for ClinVar (such as variants based solely on computational predictions) or from users who have chosen not to submit to ClinVar (such as CMT researchers outside of the United States).
As we do not want to add to the issue of multiple fragmented data collection efforts with yet another database, we will perform two-way synchronization with ClinVar at least biannually. Users should look to ClinVar for the most up-to-date variant database and utilize the INVB as a tool to view and discuss this data. We hope the simple and easy-touse interface of the INVB will facilitate communication about variant pathogenicity status among CMT researchers and clinicians and provide improved diagnostic abilities. 
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